This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.
During the course of this presentation, certain non-GAAP financial information will be presented. Additional information is available on the Company's website at www.aptar.com on the Investor's page (click on Events & Presentations for a Reconciliation of non-GAAPFinancial Measures).
Adjusted EBITDA and EPS exclude the impact of restructuring initiatives, acquisition related costs, and net unrealized investment gains and losses related to observable market price changes on equity securities. Adjusted EPS also neutralize the impact of foreign currency translation effects when comparing current results to the prior year, and further adjusts for the net effect of a tax payment related to a legal entity reorganization. Prior year Adjusted EPS includes foreign currency effects that are approximations of the adjustment necessary to state the prior year earnings per share using current period foreign currency exchange rates.
2
Agenda
Welcome, Aptar Overview
Stephan Tanda, President and CEO
Aptar Pharma Strategy and Services
Gael Touya, President, Aptar Pharma
Prescription and Consumer Healthcare
Alex Theodorakis, President, Aptar Pharma Prescription
Active Material Solutions
Badre Hammond, VP, Global Commercial Operations and GM, APAC
Aptar Digital Health
Pierre Leurent, President, Digital Health, Aptar Pharma
Elastomer Components for Injected Medicines
Gabriel Zenker, President, Aptar Pharma Injectables
Q&A
Aptar Congers and Safety Briefing Before Tour
Yann Ghafourzadeh, VP, GM Aptar Pharma North America
3
Aptar Purpose
Transforming ideas into solutions that
improve everyday life
At Our Core We Are a Technology Company
Dosing
Drug Delivery
Dispensing
5 5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
AptarGroup Inc. published this content on 15 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2022 17:21:01 UTC.
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.